HHS Accelerates Shift to Human-Based Research, Reduces Reliance on Animal Testing - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

HHS Promotes Transition to Human-Centric Research Approaches, Minimizing Animal Testing

  • By

  • Assistant Secretary for Public Affairs (ASPA)

  • September 21, 2026

Share

Clinical Scorecard: HHS Promotes Transition to Human-Centric Research Approaches, Minimizing Animal Testing

At a Glance

CategoryDetail
ConditionHuman-Centric Research Approaches
Key MechanismsUtilization of human organoids, tissue models, artificial intelligence, and computational modeling.
Target PopulationResearchers and regulatory bodies in biomedical fields.
Care SettingBiomedical research and regulatory review.

Key Highlights

  • HHS initiates over 20 efforts to reduce animal testing.
  • NIH invests over $88 million in human-based biomedical infrastructure.
  • FDA modernizes regulatory framework to incorporate nonanimal testing methods.
  • CDC reduces laboratory animal colony and enhances review procedures.
  • ARPA-H funds AI and computational modeling to improve drug safety predictions.

Guideline-Based Recommendations

Diagnosis

    Management

    • Implement human-based research methods and technologies.

    Monitoring & Follow-up

      Risks

      • Potential reduction in animal testing may impact traditional research methodologies.

      Patient & Prescribing Data

      Not specified; focuses on research and regulatory environments.

      Emphasis on developing tools that enhance understanding of human disease.

      Clinical Best Practices

      • Adopt New Approach Methodologies (NAMs) in research.
      • Utilize advanced data capabilities and robotics in laboratory settings.
      • Engage in rigorous review of proposed animal research.

      Related Resources & Content

      Original Source(s)

      HHS Accelerates Shift to Human-Based Research, Reduces Reliance on Animal Testing

      • by Assistant Secretary for Public Affairs (ASPA)

      • September 21, 2026

      Related Content

      FDA revises monitoring for SCLC therapy

      Initial monitoring decreases from 22 to 24 hours to 6 to 8 hours from the start of the first 2 infusions.

      FDA approves combo for ESR1-mutated breast cancer

      In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

      When Innovation Leaves People Behind: Reframing Accountability in Commercial Digital Health